ArticlePloS one2025
Approaches to predict future type 2 diabetes mellitus and chronic kidney disease: A scoping review.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDemographic change and changing lifestyles are leading to a steady increase in so-called population diseases such as type 2 diabetes mellitus and chronic kidney disease. Both conditions are often preceded by a latency period during which lifestyle changes and/or medications have the potential to delay or even prevent disease onset. Thus, detection of those at an increased risk of these diseases is of great importance. A scoping review was conducted to collate different prediction approaches for type 2 diabetes mellitus and chronic kidney disease.
methodsLiterature searches were performed in PubMed, Embase, Web of Science, and Google Scholar. A stepwise approach was used, consisting of searches for systematic reviews and primary literature, and additional Google searches for novel approaches. Included was literature that (1) presented an approach for risk prediction of incident type 2 diabetes mellitus or chronic kidney disease, (2) contained information on the risk factors considered and application, (3) targeted the general population, (4) was written in English or German language, and (5) for which an abstract and full-text was available. Literature screening was carried out by two persons independently.
resultsStudies extracted literature from 1940 to 2023. Prediction approaches were included from 25 literature reviews, eight primary studies and nine studies found in additional searches. Several different approaches were identified, including methods based on clinical parameters, biological parameters (blood, urine, microbiome, genetics), the combinations of those, sequential approaches, and exposure and lifestyle factors. Most of the identified approaches were risk surveys that usually ask for simple and readily available parameters. Novel approaches cover transdermal optical imaging, prediction based on facial blood flow and using deoxyribonucleic acid methylation data.
conclusionThis scoping review provides an overview of different tools for the risk prediction of type 2 diabetes mellitus and chronic kidney disease. In addition to established tools, which are primarily risk surveys, innovative approaches have been developed and evaluated in recent years in which the potential of machine learning is utilized. As cardio-renal-metabolic diseases share predicting factors and given the social and economic importance of these diseases, approaches that address multiple relevant diseases such as type 2 diabetes mellitus, chronic kidney disease and cardiovascular disease can be of great interest, especially in time- and resource-constrained healthcare settings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.